PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.261
https://www.valueinhealthjournal.com/article/S1098-3015(18)33561-7/fulltext
Section Title :
Section Order :
1949
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33561-7&doi=10.1016/j.jval.2018.09.261